Primary prevention of neural-tube defects and some other major congenital abnormalities: Recommendations for the appropriate use of folic acid during pregnancy

Paediatric Drugs

Volumn 2, Issue 6, 2000, Pages 437-449

  Czeizel, A E ^a  

^a FOUNDATION FOR THE COMMUNITY CONTROL OF HEREDITARY DISEASES   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; MULTIVITAMIN; PYRIDOXINE;

ADULT; CLEFT FACE; CONCEPTION; CONGENITAL MALFORMATION; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; FOLIC ACID DEFICIENCY; GENETIC POLYMORPHISM; HOMOCYSTINURIA; HUMAN; INCIDENCE; LIMB DEFECT; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; PRIORITY JOURNAL; REVIEW; THERMODYNAMICS; URINARY TRACT; VITAMIN SUPPLEMENTATION;

EID: 0033659941     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200002060-00003     Document Type: Review

References (72)

1. Evidence for multi-site closure of the neural tube in humans
2. Production of multiple congenital abnormalities in young by maternal pteroylglutamic acid deficiency during gestation
3. Congenital anomalies due to attempted abortion with 4-aminopteroylglutamic acid
4. Folic acid metabolism and human embryopathy
5. Vitamin deficiencies and neural tube defects
6. Neural-tube defects and derangement of homocysteine metabolism
7. Neural tube defects and elevated homocysteine levels in amniotic fluid
8. Prevention of neural tube defects by and toxicity of L-homocysteine in cultured postimplantation rat embryos
9. Folic acid: An innocuous means to reduce plasma homocysteine
10. Treatment of 'pernicious anaemia' of pregnancy and 'tropical anaemia' with special reference to yeast extract as a curative agent
11. The concentration of 'folic acid'
12. The structure and synthesis of the liver cases factor
13. A candidate genetic risk-factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
14. Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification
15. Mutated methylentetrahydrofolate reductase as a risk factor for spina bifida
16. A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects
17. Methylene-tetrahydrofolate reductase mutation and neural tube defects
18. V677T homozygosity associated with thermolabile 5,10-methylenetetrahydrofolate reductase as a risk factor for neural tube defects
19. Spina bifida, 677T→C mutation, and role of folate
20. Relevance to spina bifida of mutated methylenetetrahydrofolate reductase
21. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation
22. Heterozygote advantage of the MTHFR gene in patients with neural-tube defects and their relatives
23. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defect?
24. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
25. Analysis of select folate pathway genes, PA33, and human T in a midwestern neural tube defect population
26. Cloning, mapping and RNA analysis of the human methionine synthase gene
27. Human methionine synthase: cDNA cloning, chromosomal localisation, and identification of mutations in patients of the cbIG complementation group of folate/cobalamin disorders
28. Human methionine synthase, cDNA cloning, gene localisation and expression
29. Genetic polymorphism in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects
30. Possible prevention of neural tube defects by periconceptional vitamin supplementation
31. Prevention of neural tube defect recurrences in Yorkshire: Final report
32. Prevention of neural tube defect recurrences
33. Prevention of neural tube defects: Results of the Medical Research Council vitamin study
34. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation
35. Prevention of neural-tube defects
36. Dose-dependent effect of folic acid on the prevention of orofacial clefts
37. Population-based case-control study of folic acid supplementation during pregnancy
38. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip
39. Prevention of congenital abnormalities by periconceptional multivitamin supplementation
40. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation
41. Limb-reduction defects and folic acid supplementation
42. Periconceptional folic acid-containing multivitamin supplementation
43. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies
44. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring
45. Periconceptional multivitamin use and the occurrence of conotruncal heart defects. Results from a population-based case-control study
46. Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring?
47. Accelerated folate breakdown in pregnancy
48. Diet intake and vitamin supplement use of Hungarian women during the periconceptional period
49. Effect of increasing dietary folate on red-cell folate: Implications for prevention of neural tube defects
50. Prevention of neural tube defects
51. Knowledge and use of folic acid by women of childbearing age, United States, 1995
52. The Hungarian periconception service as a model for community genetics
53. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects
54. Prevention of neural tube defects: Clinical and public health policy
55. Prevention of neural tube defects with folic acid in China
56. 12 are independent risk factors for neural tube defects
57. 12 metabolism in families with spina bifida offspring
58. Use of folic acid for the prevention of apina bifida and other neural tube defects
59. Recommendations for the primary prevention of congenital abnormalities
60. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects
61. Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid
62. The effect of folic acid fortification on plasma folate and total homocysteine concentrations
63. 6 in Hungary
64. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease
65. Call for endorsement of petition to the Food and Drug Administration to always add vitamin B-12 to any folate fortification or supplement
66. Folate level and neural tube defects
67. Folate and cancer: A review of the literature